What is BPC-157?
BPC-157 is a lab-made peptide. A peptide is just a short chain of amino acids, the same building blocks that make up the proteins in your body. BPC-157 is a pentadecapeptide — a chain of fifteen amino acids — and the name stands for "Body Protection Compound-157." The sequence was originally based on a fragment of a protein found in human stomach fluid (gastric juice), which is also why researchers became interested in it: unlike most peptides, it appears unusually stable in that harsh, acidic environment.
It has become popular online, where people talk about it for healing tendons, joints, muscles, and the gut. But here is the part that matters most, and it comes first on purpose: BPC-157 is not an approved medicine. It is not the same kind of thing as a drug your doctor can prescribe and a pharmacy can fill. It is a research chemical — something made for laboratory study, not for people to take. A US Department of Defense supplement-safety resource states it plainly: BPC-157 "is an unapproved drug and cannot be legally prescribed or sold over the counter."
That single fact shapes everything else on this page. When something has never been approved for human use, there is no official label, no approved dose, and no quality-controlled product behind it. So the real question is not "what is the right dose" — it is "is there an established dose at all?" The honest answer is no, and the rest of this page explains why, and what the evidence does and does not actually show.
Is there an official BPC-157 dose?
No. There is no official, approved, or standard human dose for BPC-157. There is no FDA-approved BPC-157 product anywhere in the United States, so there is nothing for an official dose to even be printed on.
For a normal medicine, the dose on the label comes from years of human trials. Researchers test different amounts in real people, measure what is safe and what works, and a regulator like the FDA reviews all of it before approving a specific dose. None of that has happened for BPC-157. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine summed it up plainly: "human data are extremely limited," only three small pilot studies have ever examined BPC-157 in people — for intraarticular (into-a-joint) knee pain, interstitial cystitis, and intravenous safety and pharmacokinetics — and the authors concluded the peptide "should be considered investigational." No completed randomized controlled trial has established a dose for any use.
So when you see a confident "BPC-157 dosage protocol" online — a number of micrograms, a schedule, a number of weeks — understand what you are actually looking at. It is not coming from an approved label or a finished human trial, because neither of those exists. It is coming from somewhere far less reliable, which is the next thing worth understanding.
What 'doses' do people cite, and why be skeptical?
The dose figures that circulate online come from two places, and neither one tells you a safe or effective amount for a person.
The first source is animal studies. Almost all BPC-157 research has been done in rats and mice, not humans. In those studies, scientists used specific amounts scaled to a tiny animal's body. You cannot simply shrink or stretch an animal dose to a human one — translating a dose between species is its own careful science (it has to account for differences in metabolism, body-surface area, and how a compound is cleared), and for BPC-157 that translation has never been validated in any human trial. A number that was measured in a rat is not a human instruction.
The second source is anecdote: people on forums and social media reporting what they personally tried. That is not evidence. There is no way to know if their product was pure, if it contained what the label claimed, or whether anything they felt was caused by the peptide at all — or by the placebo effect, by the rest, ice, and rehab they were also doing, or simply by time. One person's story, repeated enough times, can start to sound like an official protocol — but repetition does not turn a guess into a tested dose. The confident precision of the numbers (down to the exact microgram) gives a false impression of science behind them.
What do the animal studies actually report?
It is fair to ask: if so many people are interested, surely something is there? The honest answer is that BPC-157 does have a real and repeatedly reported body of preclinical research — it is just animal and laboratory work, not proof of a human benefit at a human dose. Being clear about exactly what that research shows is more useful than pretending it does not exist.
The most-discussed thread is blood-vessel growth. A 2009 study found that BPC-157 modulated angiogenesis — the formation of new blood vessels — during muscle and tendon healing in animals, apparently by up-regulating VEGF (a key blood-vessel growth signal). Notably, in isolated cell cultures the same study found no direct angiogenic effect; the effect appeared only in the living, healing animal. That detail matters, because it means even the headline mechanism is context-dependent and was demonstrated in animals, not in a dish and not in people.
A separate line of work, summarised in a 2011 review, focused on the gut. Because synthetic BPC-157 is reported to be stable in human gastric juice, researchers studied it (by mouth and by injection) in animal models of gastrointestinal injury. This is genuinely interesting chemistry and biology. But "stable in a test tube of stomach acid" and "modulates healing in a rat" are hypothesis-generating findings — they tell scientists what might be worth testing in a proper human trial. They do not, by themselves, establish that the compound works in a person, let alone at what amount. The gap between "promising in animals" and "proven and dosed in humans" is exactly where most failed drugs die.
| Study / model | What it reported | Evidence quality |
|---|---|---|
| McGuire 2025 narrative review (humans) | Only three small human pilot studies; "should be considered investigational" | Very low — no completed RCT |
| Brcic 2009 (rats) | Modulated angiogenesis via VEGF in muscle/tendon healing; no direct effect in cell culture | Preclinical (animal) |
| He 2022 (rats & dogs) | Elimination half-life <~30 min; IM bioavailability ~14–19% (rats) / ~45–51% (dogs) | Preclinical (animal); no human PK |
| Sikiric 2011 review | Reported stable in human gastric juice; studied oral + injected in animal GI models | Preclinical / laboratory |
How long does BPC-157 stay in the body?
One reason people give for dosing BPC-157 several times a day is that it does not seem to last long in the bloodstream. There is animal data behind that idea, and it is worth reading precisely. A 2022 pharmacokinetic study in rats and dogs measured how injected BPC-157 moves through the body and found a very short elimination half-life — under roughly 30 minutes. The same study reported that absolute bioavailability after intramuscular injection was about 14-19% in rats and 45-51% in dogs, and that the peptide was rapidly broken down into smaller peptide fragments and amino acids and cleared through urine and bile.
Those are real numbers, but notice what they are not: they are not human numbers. That study used intravenous and intramuscular dosing in animals; it did not test a person, and it did not test oral or nasal routes. There is no published human pharmacokinetic study for BPC-157 at all. So how much of a given dose a person would absorb, how long it would last in a human body, what a minimum effective amount might be, and what an unsafe amount would be are all unknown. Using a rapid-clearance finding from rats and dogs to justify a precise human dosing frequency is exactly the kind of cross-species leap that has never been validated here.
Is BPC-157 FDA-approved or legal?
BPC-157 is not FDA-approved for any use, has no USP monograph (the quality standard a recognised medicine carries), and is not a component of any approved drug. It is sold as a "research chemical," typically labeled "not for human consumption" or "for research use only."
Its status under the compounding rules has also been a moving target, and it is easy to misread. The FDA had placed BPC-157 in "Category 2" of bulk drug substances — substances flagged as potentially presenting "significant safety risks," which compounding pharmacies were not permitted to use. In April 2026 the FDA removed BPC-157 from that Category 2 list, and its Pharmacy Compounding Advisory Committee is scheduled to review the peptide in July 2026. Here is the key point that vendors blur: removal from a "risky" list did not make BPC-157 approved. It remains an unapproved new drug in a regulatory gray zone — neither cleared for human use nor formally settled.
Two simpler lines have not moved. A US Department of Defense resource states BPC-157 cannot be legally prescribed or sold over the counter and that there is "little to no reliable scientific evidence" for its safety or effectiveness in humans. And for anyone in a tested sport, BPC-157 is on the World Anti-Doping Agency Prohibited List under category S0 (non-approved substances), banned at all times — so using it risks an anti-doping violation regardless of the form.
What are the real risks and unknowns?
The first risk is the product itself. Because BPC-157 is sold "for research use only" and labeled "not for human consumption," it is not made the way a medicine is. There is no required purity testing, no sterility guarantee, and no check that the vial contains what the label says or the amount it claims. Independent testing of research peptides has turned up the wrong contents, the wrong concentration, and contamination, and the FDA has specifically cautioned about compounded BPC-157 products over "safety risks and potential contamination with other substances." For something people inject, that is a serious problem on its own — before you even get to the peptide.
The second risk is that the safety of BPC-157 in humans has essentially never been studied. The few small pilot studies that exist did not report serious problems, but they were tiny and short, and a "no problems in a handful of people" result is a very long way from "proven safe." No one has studied what happens when someone injects it repeatedly for months. And the very mechanism that makes BPC-157 interesting — encouraging new blood-vessel growth — raises a long-standing theoretical concern: could a pro-angiogenic signal also feed something harmful, like a tumor, that depends on a blood supply to grow? That question has never been answered in people, and "we do not know" is not the same as "it is fine."
The honest summary is that BPC-157 stacks unknown on top of unknown: an unverified product, an unstudied human safety profile, no human pharmacokinetics, and a regulatory status that is unsettled rather than reassuring. None of those gaps is filled by a number copied off a forum.
Who to actually talk to
If you are trying to figure out a "dose," the honest answer is that the internet is the wrong place to get one, because no trustworthy dose exists to find. The right person to talk to is a licensed clinician — a doctor who can look at your actual health, your goals, and the real state of the evidence, and tell you straight whether any of this makes sense for you.
A good clinician will not hand you a protocol off a forum. They will explain that BPC-157 is unapproved and largely unstudied in people, walk through the genuine risks, and help you weigh options — including approved treatments that actually have human evidence behind them for tendon, joint, or gut problems. That is not them being unhelpful. That is what responsible care looks like when the evidence is this thin.
Nothing on this page is medical advice, and it is not a recommendation to use BPC-157. It is an explanation of why a confident "dose" for it does not really exist.
Tracking a clinician-supervised protocol on PeptidePanel
PeptidePanel does not sell, source, supply, prescribe, or endorse BPC-157 or any compound, and nothing here is medical advice. BPC-157 is not FDA-approved, there is no authorized prescribing pathway for it in the US, and no standard human dose exists in any official document.
PeptidePanel is a neutral record-keeping tool. If a licensed clinician is overseeing a protocol and wants it tracked, keeping a clear timeline — what was taken and when, alongside any bloodwork the clinician is watching and any effects noticed — gives a tidy, longitudinal picture over time. The value is in the organized record, not in PeptidePanel endorsing, supplying, or dosing anything. The decision always sits with the clinician and the patient.